Raiffeisen Bank International AG Buys New Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Raiffeisen Bank International AG bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 150,000 shares of the company's stock, valued at approximately $1,016,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. ProShare Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 43.8% in the fourth quarter. ProShare Advisors LLC now owns 88,158 shares of the company's stock valued at $596,000 after buying an additional 26,847 shares during the last quarter. Man Group plc acquired a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $479,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Recursion Pharmaceuticals by 5.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 165,062 shares of the company's stock valued at $1,116,000 after purchasing an additional 7,939 shares during the last quarter. Laurion Capital Management LP bought a new position in Recursion Pharmaceuticals during the fourth quarter worth $16,611,000. Finally, Ensign Peak Advisors Inc increased its holdings in shares of Recursion Pharmaceuticals by 0.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock valued at $2,774,000 after purchasing an additional 1,300 shares during the last quarter. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Trading Up 1.6%

Shares of NASDAQ:RXRX traded up $0.07 during trading on Thursday, reaching $4.16. The stock had a trading volume of 9,847,067 shares, compared to its average volume of 13,289,836. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm's fifty day moving average is $5.24 and its 200 day moving average is $6.55. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -2.73 and a beta of 0.99.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. During the same period last year, the company posted ($0.39) EPS. The business's revenue was up 7.2% compared to the same quarter last year. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on RXRX. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Needham & Company LLC decreased their price objective on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Finally, Morgan Stanley reduced their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $7.60.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.